Get Connected Efficacy Trial

Sponsor
University of Pennsylvania (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03132415
Collaborator
University of North Carolina (Other), University of Michigan (Other), University of Minnesota (Other), Emory University (Other), Children's Hospital of Philadelphia (Other), Baylor College of Medicine (Other)
285
3
2
55.9
95
1.7

Study Details

Study Description

Brief Summary

Get Connected (GC) is an online brief intervention that employs individual and systems-level tailoring technology to reduce barriers to HIV prevention care (e.g., HIV/STI testing, PrEP) for YMSM. The deployment of GC through a mobile-friendly WebApp seeks to optimize online interventions' acceptability, accessibility, availability, long-term affordability among youth. The investigators will enroll 480 self-reported HIV-negative or sero-status unaware, sexually active YMSM (ages 15-24) across three cities and randomize them into the GC intervention condition or to an attention-control condition. Assessments will be collected at 30 days and at 3, 6, 9 and 12 month follow-up.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Get Connected
  • Behavioral: HIV Test Locator
N/A

Detailed Description

The number of HIV infections among men who have sex with men aged 15-24 (YMSM) has grown significantly in the past decade. For YMSM to successfully engage in HIV prevention and care services requires that they navigate a series of multilevel barriers operating at the individual (e.g., risk awareness, self-efficacy to get tested), systems (e.g., costs, medical mistrust, lack of culturally competent care), and structural (e.g., homelessness, costs, stigma) levels.

The investigators developed Get Connected (GC) as an online brief intervention that employs individual and systems-level tailoring technology to reduce barriers to linkage to competent prevention care (e.g., HIV/STI testing, PrEP) for YMSM (ages 15-24). After a formative phase comprised of assessing HIV testing sites' performance via a mystery shopping procedure, the investigators will test the efficacy of GC for increasing YMSM's successful engagement in locally appropriate HIV prevention and care using a two-arm randomized controlled trial.

The trial will compare GC (N=240) to an existing online HIV test locator (N=240). Participants will be recruited from three cities (Houston, Philadelphia and Atlanta) characterized by high HIV incidence, and followed over 12 months. Assessments will be collected at 30 days and at 3, 6, 9 and 12 month follow-up.

Specific Aims include:

Aim 1: Examine the quality of HIV test counseling and PrEP-related referrals to YMSM within local HIV/STI testing sites in 3 cities (Houston, Philadelphia & Atlanta).

Aim 2: Test the efficacy of GC for increasing HIV-negative or HIV-unknown YMSM's successful uptake of HIV prevention services (e.g., routine HIV/STI testing) and PrEP awareness and willingness, as compared to the attention-control condition over a 12-month period.

Aim 3: Qualitatively assess sites' satisfaction with performance assessments and their improvements in service delivery when working with YMSM across the three regions.

Study Design

Study Type:
Interventional
Actual Enrollment :
285 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Get Connected: Linking YMSM to Adequate Care Through a Multilevel, Tailored WebApp Intervention
Actual Study Start Date :
Nov 1, 2017
Actual Primary Completion Date :
Dec 15, 2021
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Get Connected

Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.

Behavioral: Get Connected
The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.

Active Comparator: Non-tailored HIV Test Locator

Participants randomized to the control condition will be directed to a testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.

Behavioral: HIV Test Locator
The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.

Outcome Measures

Primary Outcome Measures

  1. Percent of Participants reporting changes in their HIV Testing Behavior using self-report questionnaires [30-day, 3-month, 6-month, 9-month, and 12-month follow-up assessments]

    The investigators will estimate the proportion of participants who test for HIV by intervention group and by time on study.

Secondary Outcome Measures

  1. Percent of participants reporting changes in PrEP uptake using self-report questionnaires [30-day, 3-month, 6-month, 9-month, and 12-month follow-up assessments]

    The investigators will test the proportion of the sample that begins PrEP during the 12-month follow-ups.

  2. Mean Change in motivations to engage in HIV prevention behaviors using self-report questionnaires [30-day, 3-month, 6-month, 9-month, and 12-month follow-up assessments]

    The investigators will measure the change in HIV prevention attitudes, norms, and self-efficacy using the NIH Adolescent Trials Network's Harmonized Questionnaire by intervention group and by time on study.

  3. Mean Change in PrEP motivations using self-report questionnaires [30-day, 3-month, 6-month, 9-month, and 12-month follow-up assessments]

    The investigators will measure the change in PrEP awareness and willingness over time using the NIH Adolescent Trials Network's Harmonized Questionnaire.

  4. Percent of Participants reporting changes in their STI Testing Behavior using self-report questionnaires [30-day, 3-month, 6-month, 9-month, and 12-month follow-up assessments]

    The investigators will estimate the proportion of participants who test for STIs at least once over the trial period.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 24 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Assigned male sex at birth and currently identifies as male

  • Aged 15 to 24 years (inclusive) at time of screening

  • Self-report as HIV-negative or sero-status unaware

  • Speak and read English

  • Not be on PrEP at time of enrollment

  • Report having consensual anal sex with a male partner in the prior 6 months

  • Reside in Philadelphia, Houston, or Atlanta

  • Access to internet

Exclusion Criteria:
  • Assigned female sex at birth

  • Assigned male sex at birth but identifies as transgender or gender non-conforming

  • Aged 14 years or younger or 25 years or older at time of screening

  • HIV-positive

  • Does not speak or read English

  • Currently taking PrEP

  • Did not have consensual anal sex with a male partner in the prior 6 months

  • Does not reside in Philadelphia, Houston, or Atlanta

  • Currently incarcerated

  • Planning to move out of the region in next 12 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Emory University Atlanta Georgia United States 30322
2 Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19104
3 Texas Children's Hospital Houston Texas United States 77030

Sponsors and Collaborators

  • University of Pennsylvania
  • University of North Carolina
  • University of Michigan
  • University of Minnesota
  • Emory University
  • Children's Hospital of Philadelphia
  • Baylor College of Medicine

Investigators

  • Study Chair: Lisa Hightow-Weidman, MD, University of North Carolina
  • Principal Investigator: Jose A Bauermeister, PhD, University of Pennsylvania
  • Principal Investigator: Rob B Stephenson, PhD, University of Michigan
  • Study Chair: Patrick S Sullivan, PhD, Emory University

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT03132415
Other Study ID Numbers:
  • 1U19HD089881 (SubProject 8780)
  • 1U19HD089881
First Posted:
Apr 27, 2017
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Pennsylvania
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022